Financial Data and Key Metrics Changes - The company reported adjusted earnings of $5,600,000 or €0.14 per share for the first quarter of 2025, with EBITDAR of $18,500,000 [8][24] - The cash breakeven level is maintained at $11,500 per day, with a lower level of $10,500 per day when excluding pro forma CapEx [23] - The company declared a quarterly cash dividend, consistent with its policy of paying out one third of adjusted earnings [8] Business Line Data and Key Metrics Changes - MR tankers earned $20,900 per day in the first quarter and $22,100 per day so far in the second quarter with 50% booked [11] - Chemical tankers earned $15,000 per day in the first quarter and $19,500 per day in the second quarter with 60% booked [11] Market Data and Key Metrics Changes - The MR fleet is currently the oldest since the turn of the century, with an average age of over 14 years, and more than half will be over 20 years old within the next five years [15][16] - The current order book represents only 14% of the fleet, indicating a significant supply-demand imbalance [15] - The sanctioned fleet has increased by 80% since the start of the year, affecting supply dynamics favorably for compliant fleets [19] Company Strategy and Development Direction - The company is focused on balancing cash returns to shareholders with reinvestment in the fleet to enable sustainable value creation [11] - Investments in efficiency projects are ongoing, with expected IRRs ranging from 20% to over 100% [12] - The company is upgrading tank coatings on chemical tankers to enhance cargo flexibility and revenue opportunities [12] Management's Comments on Operating Environment and Future Outlook - Management highlighted the resilience of product freight markets despite broader market turmoil, supported by strong refining margins and OPEC oil production increases [7][20] - The company remains cautious about fleet expansion and modernization due to current asset value corrections, monitoring opportunities closely [38][50] Other Important Information - The company announced the retirement of COO Marc Cameron, effective January 1, and the promotion of Robert Gayner to COO [29][30] - John Russell will take on the role of CFO effective July 1, promoting from within the organization [31] Q&A Session Summary Question: Fleet update regarding time charter arrangements - The company is exploring opportunities for both charter in and charter out, maintaining a good relationship with head owners [34][36] Question: Management changes and strategic implications - Management emphasized continuity in strategy and governance despite leadership changes, with a strong internal talent pool [44][46] Question: Impact of OPEC production increases on MR market - Management noted that OPEC production increases positively affect refining margins, which in turn supports the demand for transportation of refined products [48][50]

Contents I. Highlights Ardmore Shipping First Quarter 2025 Disclaimer This presentation contains certain statements that may be deemed to be "forward-looking statements" within the meaning of applicable U.S. federal securities laws. All statements, other than statements of historical facts, that address activities, events or developments that Ardmore Shipping Corporation ("Ardmore" or the "Company") expects, projects, believes or anticipates will, or may occur in the future, are among these forward-looking ...

Group 1: Earnings Performance - Ardmore Shipping reported quarterly earnings of $0.14 per share, missing the Zacks Consensus Estimate of $0.15 per share, and down from $0.92 per share a year ago, representing an earnings surprise of -6.67% [1] - The company posted revenues of $42.96 million for the quarter, missing the Zacks Consensus Estimate by 2.86%, and down from $75.75 million year-over-year [2] - Over the last four quarters, Ardmore Shipping has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times [2] Group 2: Stock Performance and Outlook - Ardmore Shipping shares have declined approximately 18.5% since the beginning of the year, compared to a decline of -4.7% for the S&P 500 [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the upcoming quarter is $0.14 on revenues of $37.75 million, and for the current fiscal year, it is $0.88 on revenues of $177.83 million [7] Group 3: Industry Context - The Transportation - Shipping industry, to which Ardmore Shipping belongs, is currently ranked in the bottom 11% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Ardmore Shipping's stock performance [5][6]

HONG KONG, May 6, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces oral and poster presentations on preliminary studies of ASC47, an adipose-targeted, muscle-preserving weight loss drug candidate for obesity, will be presented at the 32nd European Congress On Obesity (ECO 2025) in Malaga, Spain. For more information, please visit http://www.ascletis.com. Title: ASC47, a Muscle-Preserving Weight Loss Drug Candidate in Healthy Participants: A First-in-human Single Ascending Dose Stu ...

Core Insights - ZyVersa Therapeutics, Inc. has announced new data supporting its Inflammasome ASC Inhibitor IC 100 as a potential treatment to slow the progression of Parkinson's disease [1][2] - The study published in npj Parkinson's Disease reveals that IC 100 blocks microglial inflammasome activation and reduces neurotoxic alpha-synuclein accumulation, both of which are critical in the progression of Parkinson's disease [2][7] Company Overview - ZyVersa is a clinical stage specialty biopharmaceutical company focused on developing first-in-class drugs for inflammatory and renal diseases, with a strong position in the inflammasome space [10] - The company is preparing to initiate proof-of-concept studies for IC 100 in animal models later this year [3] Study Findings - The research indicates that targeting inflammasomes and ASC specks may also be beneficial for treating Lewy body dementia and Alzheimer's Disease [5] - IC 100 is a humanized IgG4 monoclonal antibody designed to inhibit the inflammasome adaptor protein ASC, which plays a role in the inflammatory response [6] Market Context - Parkinson's Disease affects over 10 million people globally, with the current treatment market valued at $6.6 billion in 2024 and projected to reach $13.3 billion by 2034 [7] - Current treatments primarily address symptoms rather than the underlying disease, highlighting the potential market opportunity for disease-modifying therapies like IC 100 [7]

Company Overview - Ardmore Shipping Corporation operates a fleet of MR product and chemical tankers with deadweight tonnage ranging from 25,000 to 50,000 [3] - The company provides seaborne transportation of petroleum products and chemicals globally to various clients including oil majors and chemical companies [3] Earnings Announcement - Ardmore plans to announce its first quarter earnings on May 7, 2025, before the market opens [1] - A conference call will be held on the same day at 10:00 a.m. Eastern Time, which will also be available via live webcast [1][2] Strategic Focus - The core strategy of Ardmore includes developing a modern, high-quality fleet, building long-term commercial relationships, and maintaining cost advantages [4] - The company aims to create synergies and economies of scale as it grows [4] Energy Transition Plan - Ardmore's Energy Transition Plan focuses on transition technologies, projects, and sustainable non-fossil fuel cargos [5] - This plan is an extension of the company's strategy, leveraging its strengths in tanker chartering and operational efficiency [5]

Core Insights - Ascletis Pharma Inc. announced positive interim results from a Phase Ib study of ASC30, a small molecule GLP-1 receptor agonist, demonstrating a 36-day half-life for its ultra-long-acting subcutaneous injection formulation in patients with obesity [2][4][8] - The oral tablet formulation of ASC30 showed a potential best-in-class weight loss of 6.3% after four weeks of treatment [5] Group 1: Study Results - The Phase Ib study involved three ultra-long-acting subcutaneous injection formulations of ASC30, with one formulation achieving a 36-day half-life, supporting less frequent administration [3][4] - The study included eight patients receiving the ASC30 formulation and two on placebo, indicating a well-structured clinical trial design [3] Group 2: Safety Profile - ASC30 SQ injection was well tolerated, with no serious adverse events reported and the majority of gastrointestinal-related adverse events being mild [6] - No significant elevations in liver enzymes or abnormal findings in laboratory tests were observed, indicating a favorable safety profile [6] Group 3: Product Development - ASC30 is designed for both once-daily oral and once-monthly subcutaneous administration, providing flexibility in treatment options for obesity [7][9] - The formulation is stable around neutral pH, allowing for potential co-formulation with other drugs, which could enhance its therapeutic applications [4] Group 4: Market Implications - The once-monthly injection could significantly reduce the number of devices and cartridges needed compared to weekly injectables, potentially improving patient compliance and convenience [8] - The unique properties of ASC30 as a small molecule GLP-1R biased agonist position it favorably in the obesity treatment market [9][10]

Group 1 - Ardmore Shipping Corporation (NYSE: ASC) is currently trading at half its net asset value (NAV), indicating a potential investment opportunity as such anomalies typically do not persist for long [1] - The company has initiated share buybacks for the first time since its inception, signaling confidence in its valuation and future prospects [1] - Ardmore Shipping Corporation is considered a prime candidate for further investment due to its current undervaluation and strategic actions [1]

Group 1 - Ardmore Shipping's stock closed at $10.08, showing a +0.9% increase, outperforming the S&P 500's loss of 1.12% [1] - The stock has increased by 2.04% over the past month, while the Transportation sector declined by 3.72% and the S&P 500 fell by 2.91% [1] Group 2 - Ardmore Shipping is expected to report earnings of $0.20 per share, reflecting a year-over-year decline of 78.26%, with projected quarterly revenue of $44.23 million, down 41.61% from the previous year [2] - For the annual period, earnings are anticipated to be $1.06 per share and revenue at $177.83 million, indicating declines of -62.68% and -34.9% respectively [3] Group 3 - Recent changes in analyst estimates for Ardmore Shipping suggest optimism regarding the company's business and profitability [3] - The Zacks Rank system indicates that Ardmore Shipping currently holds a rank of 3 (Hold), with no changes in the consensus EPS estimate over the past month [5] Group 4 - Ardmore Shipping's Forward P/E ratio is 9.42, which is higher than the industry's Forward P/E of 8.92 [6] - The Transportation - Shipping industry is ranked 170 in the Zacks Industry Rank, placing it in the bottom 33% of over 250 industries [6]

Core Insights - Ascletis Pharma Inc. announced positive pharmacokinetic and weight loss data for its drug candidate ASC47 from Phase Ib studies in Australia, targeting obesity and elevated LDL-C levels [1][8] Group 1: Drug Efficacy and Mechanism - ASC47 demonstrated a half-life of up to 26 days in healthy subjects and 40 days in patients with obesity, supporting administration every month to every two months [2][8] - In patients with obesity, ASC47 showed a placebo-adjusted mean weight loss of 0.2% at day 29, 1.0% at day 43, and peaked at 1.7% at day 50, indicating a slower weight loss rate due to its mechanism of action involving UCP-1-mediated thermogenesis [3][8] - ASC47 resulted in significant placebo-adjusted reductions in LDL-C by up to 22% and total cholesterol by up to 16%, confirming its target engagement in humans [4][8] Group 2: Safety and Tolerability - ASC47 was well tolerated at doses up to 90 mg, with no serious adverse events reported and most adverse events being mild [5][8] - There were no significant changes in heart rate or liver enzymes, indicating a favorable safety profile [5][8] Group 3: Future Development Plans - A multiple ascending dose study of ASC47 for obesity treatment is expected to begin in the second half of 2025 [5][9] - The U.S. FDA has cleared an IND application for ASC47 in combination with semaglutide, with the first patient expected to be dosed by the end of Q2 2025 [7][8] Group 4: Company Overview - Ascletis Pharma Inc. is a biotech company focused on R&D, covering the entire value chain from drug discovery to GMP manufacturing, with a focus on metabolic and viral diseases [14]